查看文章

Dear Editor, A recent article reported the useful results of autoantibodies in coronavirus disease 2019 (COVID-19). 1 We obtained additional results of autoantibodies, especially antinuclear antibody (ANA) tested by the same indirect immunofluorescence assay (IFA), in moderate and critical cases of COVID-19. We enrolled 47 hospitalized patients with COVID-19 confirmed by real-time polymerase chain reaction (PCR), who were classified as either moderate (31 cases; pneumonia but no need for oxygenation) or critical (16 cases; pneumonia and need for oxygenation or mechanical ventilation therapy or death) based on the severity scoring system. 2 ANA and anti-cyclic citrullinated peptide (CCP) antibody were measured in serum or plasma samples within 3 weeks after PCR confirmation. ANA was evaluated by IFA using ANA HEp-2 Test System (ZEUS Scientific), and anti-CCP antibody l was measured by chemiluminescent microparticle immunoassay using ARCHITECT (Abbott Laboratories). Table 1 shows the demographics of patients and prevalence of autoantibodies. The total positive rate of ANA was 21.3%(10/47), whereas previous studies have been 33.5%(11/33), 1 57.5%(23/40), 3 or 50%(10/20). 4 Variability in the prevalence could be due to the small sample sizes, different assay methods, and different groups of patients enrolled. The total positive rate of anti-CCP antibody was 2.1%(1/47), which was lower than 20%(2/10) 5 reported earlier. Pascolini et al. documented 36.3%(4/11) nucleolar and 36.3%(4/11) speckled staining among ANA-positive cases. 1 Our results revealed the same dominant patterns of 50%(5/10) nucleolar and …